Critical Advances in Systemic Therapy for HCC: Building on Recent Progress for Community Practices

Explore recent data surrounding contemporary HCC treatment with this program featuring expert commentaries an on-demand Webcast and downloadable slides.

Share

Program Content

Activities

Atezo + Bev in Adv HCC
A New Regimen for Advanced HCC: Atezolizumab Plus Bevacizumab
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 15, 2020

Expires: September 14, 2021

Transitioning Therapy
Key Concepts in HCC Treatment: Transitioning Patients From Locoregional to Systemic Therapy
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 20, 2020

Expires: October 19, 2021

HCC With Child-Pugh B
How I Select Systemic Therapy for Patients With Advanced HCC and Child-Pugh B Cirrhosis
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 18, 2020

Expires: November 17, 2021

Activities

HCC Treatment
Critical Advances in Systemic Therapy for HCC: Building on Recent Progress for Community Practices
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 19, 2020

Expires: November 18, 2021

<i>EP</i>: HCC Treatment
ExpressPoints: Critical Advances in Systemic Therapy for HCC: Building on Recent Progress for Community Practices
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 30, 2020

Expires: November 29, 2021

No activities added yet

Faculty

cover img faculity

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Eisai

Exelixis, Inc.

Genentech, a member of the Roche Group

Lilly

Merck Sharp & Dohme Corp.